Table 5.
Clinical characteristics of subjects treated with only ceftaroline
| Study | Structural lung diseasea, n (%) | Congestive heart failure, n (%) | Prior pneumonia, n (%) | GERD, n (%) | Smoking, n (%) | Prior antimicrobial therapy, n (%) |
|---|---|---|---|---|---|---|
| Guervil et al, 2015 [16] | 161 (40.7) | 79 (20.0) | 98 (24.8) | 91 (23.0) | 114 (28.8) | 396 (100.0) |
| Udeani et al....., 2014 [17] | 228 (43.2) | 113 (21.4) | 134 (25.4) | 127 (24.1) | 159 (30.1) | – |
| Ramani et al.., 2014 [18] | 162 (40.7) | 80 (20.1) | 98 (24.6) | 92 (23.1) | 114 (28.6) | 328 (82.4) |
| Vasquez et al..., 2015 [19] | – | – | – | – | – | 18 (85.7) |
| Casapao et al......, 2014 [20] | – | – | – | – | – | – |
| Kaye et al., 2015 [21] | 19 (47.5) | 8 (0.20) | 10 (25.0) | 10 (25.0) | 21 (52.5) | – |
aDefined as any chronic parenchymal or airway disease [e.g. chronic obstructive pulmonary disease (emphysema, chronic bronchitis), bronchiectasis, or interstitial fibrosis]